BioCentury | Jun 13, 2020
Translation in Brief

OSE identifies myeloid checkpoint target; plus a call from NCI for COVID-19 test proposals, Sinopharm vaccine data and more

mAbs against new myeloid checkpoint  OSE Immunotherapeutics S.A. (Euronext:OSE) has identified CLEC1A, a carbohydrate-binding protein, as a tumor myeloid checkpoint target, and has generated mAbs that prevent CLEC1A from binding its ligand on tumor cells....
BioCentury | Jun 11, 2020

Cullinan adds first-in-class asset in hot NK cell checkpoint space

The latest addition to Cullinan’s oncology portfolio is a mAb against MICA that’s set to become the first compound in the clinic against the NK cell target. Through a deal announced on Thursday, Cullinan Oncology...
BioCentury | May 29, 2020
Distillery Therapeutics

Blocking platelet activation for acetaminophen-induced liver failure

DISEASE CATEGORY: Hepatic INDICATION: Liver failure Inhibiting signaling by the platelet activating receptor CLEC1B could treat acetaminophen-induced liver failure. mRNA levels of PDPN, the cognate ligand of CLEC1B, were higher in tissue from acetaminophen-injured human...
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

Center stage at this year’s virtual ASCO meeting are a series of hot topics that demonstrate the transformative potential of a single data readout or regulatory update. Areas to watch include next-generation checkpoint targets, where...
BioCentury | Apr 22, 2020

April 21 Financial Quick Takes: ORIC’s IPO plans; plus venture rounds for Magpie, Cloudbreak, ReAlta, New Horizon, Zikani

ORIC sets terms for planned IPO In an updated prospectus, oncology company ORIC Pharmaceuticals Inc. proposed to sell 5 million shares at $14-$16 in a planned IPO on NASDAQ. At the midpoint, a sale of...
BioCentury | Apr 1, 2020
Product Development

Chinese data propel InflaRx anti-complement mAb into clinic for severe COVID-19 pneumonia

Backed by preclinical and clinical data that support blocking complement to mitigate coronavirus-mediated respiratory distress, InflaRx has begun a clinical study of its own complement inhibitor to treat COVID-19 patients with severe pneumonia. InflaRx N.V....
BioCentury | Jan 31, 2020
Distillery Therapeutics

CLEC14A-positive stem cell transplants for muscle regeneration

DISEASE CATEGORY: Musculoskeletal INDICATION: Musculoskeletal Transplantation with muscle-derived CLEC14A-positive stem cells could regenerate muscle following injury, despite lacking expression of known myogenic regulator PAX7. The myogenic cells were isolated from muscle fiber fragments that underwent...
BC Extra | Jan 30, 2020
Company News

As Spinraza’s sales level off, Biogen presses ahead with aducanumab plans

Although Biogen’s earnings report suggests sales of SMA therapy Spinraza have plateaued, the company signaled its continued optimism that FDA will approve another potential blockbuster, its Alzheimer’s disease treatment aducanumab. Revenues from Spinraza nusinersen dipped...
BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

As drug developers try to crack the code for making CAR T cell therapies work in solid tumors, they aren’t sticking to the playbook that led to success with other modalities. BioCentury’s analysis of the...
BioCentury | Jan 4, 2020
Targets & Mechanisms

SIGLECs go from homing beacons to next-generation checkpoints

Propelled by growing understanding of their biology, and an expression pattern that goes well beyond T cells, SIGLEC proteins are rising as the next set of checkpoint targets to challenge PD-1. The sugar-binding proteins could...
Items per page:
1 - 10 of 311